eli lilly announced a plan to invest at least $27 billion in new U.S. manufacturing sites to meet the rising demand for its weight loss and diabetes drugs, amidst a backdrop of reshoring manufacturing and enhancing supply chains.

eli lilly plans to invest at least $27 billion in new manufacturing sites in the U.S. as demand for its drugs increases.

eli lilly CEO david ricks commented on the company's commitment to domestic manufacturing.

Competing with eli lilly's drugs zepbound and mounjaro in the GLP-1 market.